The First Case of Daratumumab-Induced Fulminant Hepatic Failure

Drug-induced liver failure is a relatively uncommon condition with a vast spectrum of clinical manifestations, and it is a leading cause of acute hepatic failure in the United States. We describe the first case of fulminant hepatic failure induced by chemotherapeutic drug daratumumab, a common FDA-a...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2023-10, Vol.15 (10)
Main Authors: Alvi, Ali Tariq, George Mathew, Sachin, Shankar, Murali
Format: Article
Language:English
Subjects:
Abdomen
Analgesics
Antibiotics
Blood
Cellulitis
Chemotherapy
Cytomegalovirus
Drug dosages
FDA approval
Gastroenterology
Hemoglobin
Hepatitis
Hospitals
Immunotherapy
Internal Medicine
Leukocytes
Liver
Metabolism
Monoclonal antibodies
Multiple myeloma
Oncology
Phosphatase
Targeted cancer therapy
Thrombocytopenia
Tomography
Toxicity
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Drug-induced liver failure is a relatively uncommon condition with a vast spectrum of clinical manifestations, and it is a leading cause of acute hepatic failure in the United States. We describe the first case of fulminant hepatic failure induced by chemotherapeutic drug daratumumab, a common FDA-approved agent. A 77-year-old male, with a history of multiple myeloma, was admitted for left lower extremity cellulitis, two weeks after receiving his first intravenous infusion of daratumumab. He developed fulminant hepatic failure in the hospital a few days later. Despite multiple doses of N-acetylcysteine, his liver function continued to decline, and he expired shortly after.
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.46858